[go: up one dir, main page]

MX2017006565A - Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr). - Google Patents

Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).

Info

Publication number
MX2017006565A
MX2017006565A MX2017006565A MX2017006565A MX2017006565A MX 2017006565 A MX2017006565 A MX 2017006565A MX 2017006565 A MX2017006565 A MX 2017006565A MX 2017006565 A MX2017006565 A MX 2017006565A MX 2017006565 A MX2017006565 A MX 2017006565A
Authority
MX
Mexico
Prior art keywords
intermediates
alpha
alkyl
production
fxr modulators
Prior art date
Application number
MX2017006565A
Other languages
English (en)
Other versions
MX375865B (es
Inventor
Weymouth-Wilson Alexander
Komsta Zofia
Boydell James
Otter Carl
WALLIS Laura
BATCHELOR Rhys
DAVIES Ieuan
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1505676.5A external-priority patent/GB201505676D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006565A publication Critical patent/MX2017006565A/es
Publication of MX375865B publication Critical patent/MX375865B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula (I) en donde R1, R2, Y1, R4 y R5 son como se definen aquí; los compuestos son intermedios en la síntesis de ácidos biliares sintéticos.(ver Fórmula).
MX2017006565A 2014-11-19 2015-11-19 Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr). MX375865B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505676.5A GB201505676D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053518 WO2016079519A1 (en) 2014-11-19 2015-11-19 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006565A true MX2017006565A (es) 2018-01-26
MX375865B MX375865B (es) 2025-03-07

Family

ID=54704021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006565A MX375865B (es) 2014-11-19 2015-11-19 Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).

Country Status (13)

Country Link
US (1) US10538550B2 (es)
EP (1) EP3221333B1 (es)
JP (1) JP6735748B2 (es)
KR (1) KR102546748B1 (es)
CN (1) CN107108688B (es)
CA (1) CA2968305A1 (es)
DK (1) DK3221333T3 (es)
EA (1) EA034739B1 (es)
ES (1) ES2748692T3 (es)
MX (1) MX375865B (es)
PL (1) PL3221333T3 (es)
TW (1) TWI686401B (es)
WO (1) WO2016079519A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
JP2018538331A (ja) * 2015-12-22 2018-12-27 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸の多型結晶形態
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020041673A1 (en) 2018-08-23 2020-02-27 President And Fellows Of Harvard College Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
EP3890745B1 (en) * 2018-12-04 2025-11-19 President and Fellows of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7138390B2 (en) * 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
US20090062256A1 (en) * 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP2112995B1 (en) 2007-01-19 2013-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
CN105037476B (zh) 2008-07-30 2018-06-12 英特塞普特医药品公司 Tgr5调节剂及其使用方法
EP2376519B1 (en) 2008-11-19 2013-11-13 Intercept Pharmaceuticals, Inc. Tgr5 modulators and method of use thereof
ES2592452T3 (es) * 2008-11-19 2016-11-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y métodos de uso de los mismos
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
SG11201408501UA (en) * 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
AU2013334122B2 (en) 2012-10-26 2017-11-02 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
NZ708501A (en) * 2012-11-28 2019-03-29 Intercept Pharmaceuticals Inc Treatment of pulmonary disease
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
PT2997035T (pt) 2013-05-14 2018-07-18 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e seus conjugados de aminoácido como moduladores do recetor farnesoide x
HK1223361A1 (zh) 2013-05-24 2017-07-28 Société des Produits Nestlé S.A. 用於预测肠易激综合征诊断的途径特异性测定
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN106661079B (zh) 2014-05-29 2019-03-01 巴尔制药有限公司 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
PL3221332T3 (pl) 2014-11-19 2019-10-31 Nzp Uk Ltd Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
CN107771180B (zh) 2015-06-19 2021-03-23 英特塞普特医药品公司 Tgr5调节剂及其使用方法
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
TWI686401B (zh) 2020-03-01
US20180340006A1 (en) 2018-11-29
JP2017538690A (ja) 2017-12-28
TW201632538A (zh) 2016-09-16
EA201790879A1 (ru) 2017-11-30
CA2968305A1 (en) 2016-05-26
JP6735748B2 (ja) 2020-08-05
EP3221333B1 (en) 2019-07-24
US10538550B2 (en) 2020-01-21
KR102546748B1 (ko) 2023-06-22
PL3221333T3 (pl) 2020-01-31
KR20170104453A (ko) 2017-09-15
EP3221333A1 (en) 2017-09-27
DK3221333T3 (da) 2019-09-30
HK1244287A1 (en) 2018-08-03
WO2016079519A9 (en) 2018-08-09
CN107108688A (zh) 2017-08-29
CN107108688B (zh) 2019-10-29
ES2748692T3 (es) 2020-03-17
WO2016079519A1 (en) 2016-05-26
EA034739B1 (ru) 2020-03-16
MX375865B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006563A (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006567A (es) Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
MX2017006564A (es) Esteroides 5.beta.-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
MX378186B (es) Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
CR20160448A (es) Nuevos derivados de piridina
MX2016000551A (es) Proceso novedoso para la preparacion de pirrolidina-dionas espiroheterociclicas.
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX382659B (es) Proceso para la preparación de derivados de tiazol.
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina
MX376760B (es) Proceso para la fabricación de derivados de 3-piperazin-1-il-propilamina.

Legal Events

Date Code Title Description
FG Grant or registration